转移性甲状腺癌中与放射性碘亲和性相关的基因改变特征
回顾性纳入214例分化型甲状腺癌远处转移患者,按首次治疗后扫描的碘摄取模式分为初始碘难治(I-RAIR)和初始碘亲和(I-RAIA),后者再分为持续亲和、部分难治和逐渐难治。BRAF、TERT启动子和TP53突变在I-RAIR中更常见,RET融合和RAS突变在I-RAIA中更常见;I-RAIR中晚期打击突变(TERT、TP53或PIK3CA)比例高于I-RAIA(50.0% vs 26.9%,P=0.001)。
要点
- BRAF、TERT启动子和TP53突变在初始碘难治模式中更常见,RET融合和RAS突变在初始碘亲和模式中更常见。
- I-RAIR中晚期打击突变(TERT、TP53或PIK3CA)比例为50.0%,高于I-RAIA的26.9%(P=0.001)。
- BRAFV600E突变肿瘤的I-RAIR模式比例为64.4%,高于RAS突变肿瘤的4.5%(P<0.001)和融合阳性肿瘤的20.7%(P<0.001)。
核心结论
- 初始碘难治模式患者以BRAF和/或TERT启动子突变为主要特征,其中RAS突变通常伴随晚期打击突变,而融合多单独出现。
研究设计与样本
- 回顾性纳入214例分化型甲状腺癌远处转移患者,根据首次治疗后扫描定义初始碘难治(I-RAIR)和初始碘亲和(I-RAIA),I-RAIA再分为持续碘亲和(C-RAIA)、部分碘难治(P-RAIR)和逐渐碘难治(G-RAIR)。
- 按主要驱动基因状态分为BRAFV600E突变、RAS突变、融合和其他分子亚型组。
主要发现
- BRAF、TERT启动子和TP53突变在I-RAIR模式中更频繁检出,RET融合和RAS突变在I-RAIA模式中更频繁检出。
- 晚期打击突变包括TERT、TP53或PIK3CA,在I-RAIR中较I-RAIA更常见(50.0% vs 26.9%,P=0.001),尤其在I-RAIR组中RAS突变者常伴随TERT启动子。
- 孤立RET融合占I-RAIR的10%。
- BRAFV600E突变肿瘤的I-RAIR模式比例为64.4%,高于RAS突变肿瘤的4.5%(P<0.001)和融合阳性肿瘤的20.7%(P<0.001)。
- 在I-RAIA亚组中,BRAFV600E突变肿瘤的C-RAIA模式比例低于RAS突变或融合肿瘤。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Patients with differentiated thyroid cancer (DTC) with distant metastasis (DM) are usually not recognized as radioactive iodine (RAI)-refractory DTC in a timely manner. The elucidation of genetic features related to RAI uptake patterns may shed light on the early recognition of RAI-refractory DTC. OBJECTIVE: This work aimed to elucidate the underlying molecular features behind different RAI uptake patterns. METHODS: A total of 214 patients with DM-DTC were retrospectively included in the analysis. RAI uptake patterns were defined as initially RAI refractory (I-RAIR) and initially RAI avid (I-RAIA) according to the first post-treatment scan, then I-RAIA was further divided into continually RAIA (C-RAIA), partly RAIR (P-RAIR), and gradually RAIR (G-RAIR) according to subsequent scans. The molecular subtype groups-BRAFV600E mutated, RAS mutated, fusions, and others-were classified according to main driver genes status. RESULTS: BRAF, TERT promoter, and TP53 mutations are more frequently detected in the I-RAIR pattern while RET fusions and RAS mutations are more frequent in the I-RAIA pattern. A late-hit mutation including TERT, TP53, or PIK3CA is more common in I-RAIR than that in I-RAIA (50.0% vs 26.9%, P = .001), particularly for those with RAS mutations in the I-RAIR group, always accompanied by TERT promoter. Isolated RET fusions accounts for 10% of I-RAIR. When compared among driver gene groups, BRAFV600E-mutated tumors have a higher rate of the I-RAIR pattern (64.4%) than RAS-mutated (4.5%, P < .001) and fusion-positive (20.7%, P < .001) tumors. In I-RAIA subgroups, BRAFV600E-mutated tumors have lower prevalence of the C-RAIA pattern than those with RAS mutation or fusions. CONCLUSION: Patients with the I-RAIR pattern predominantly featured mutations of the BRAF and/or TERT promoter, of which RAS mutations were usually accompanied by late-hit mutations, while fusions mostly occurred alone.
引用
- Mu Z, Zhang X, Sun D, et al. Characterizing Genetic Alterations Related to Radioiodine Avidity in Metastatic Thyroid Cancer. J Clin Endocrinol Metab. 2024. PMID: 38060243. doi:10.1210/clinem/dgad697
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。